Xencor, Inc. (XNCR)

NASDAQ: XNCR · IEX Real-Time Price · USD
22.23
-0.22 (-0.98%)
May 25, 2022 4:00 PM EDT - Market closed
Market Cap1.32B
Revenue (ttm)326.64M
Net Income (ttm)108.71M
Shares Out59.54M
EPS (ttm)1.78
PE Ratio12.50
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume215,311
Open22.42
Previous Close22.45
Day's Range22.05 - 23.07
52-Week Range21.98 - 43.61
Beta0.80
AnalystsBuy
Price Target53.19 (+139.3%)
Earnings DateMay 5, 2022

About XNCR

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Its product candidates include Plamotamab, a tu...

IndustryBiotechnology
IPO DateDec 3, 2013
CEOBassil Dahiyat
Employees254
Stock ExchangeNASDAQ
Ticker SymbolXNCR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 20 analysts, the average rating for XNCR stock is "Buy." The 12-month stock price forecast is 53.19, which is an increase of 139.27% from the latest price.

Price Target
$53.19
(139.27% upside)
Analyst Consensus: Buy
Stock Forecasts

News

7 High-Risk, High-Reward Small-Cap Stocks to Buy Now

Many small-cap stocks in the S&P 600 Small Cap Index aren't big names, but they have the change of bringing big rewards. The post 7 High-Risk, High-Reward Small-Cap Stocks to Buy Now appeared first on I...

1 week ago - InvestorPlace

Xencor (XNCR) Beats Q1 Earnings and Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of 155.71% and 302.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Xencor Reports First Quarter 2022 Financial Results

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseas...

2 weeks ago - Business Wire

3 Best Profitable Stocks to Buy Using Net Income Ratio

Xencor (XNCR), Encore Wire (WIRE) & Silvergate Capital (SI) have been selected as the top profitable picks with a high net income ratio.

Other symbols:SIWIRE
2 weeks ago - Zacks Investment Research

Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune disea...

3 weeks ago - Business Wire

Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Researc...

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune disea...

1 month ago - Business Wire

Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR...

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune disea...

2 months ago - Business Wire

Xencor (XNCR) Q4 Earnings and Revenues Beat Estimates

Xencor (XNCR) delivered earnings and revenue surprises of 157.45% and 42.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Xencor Reports Fourth Quarter and Full Year 2021 Financial Results

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseas...

3 months ago - Business Wire

Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of patients with can...

3 months ago - Business Wire

Xencor (XNCR) to Report Q4 Results: Wall Street Expects Earnings Growth

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Xencor to Present at Upcoming Investor Conferences

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...

3 months ago - Business Wire

Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...

4 months ago - Business Wire

Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...

4 months ago - Business Wire

Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...

5 months ago - Business Wire

Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

MONROVIA, Calif., HONG KONG & BOSTON--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment...

6 months ago - Business Wire

Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annu...

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...

6 months ago - Business Wire

Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the...

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...

6 months ago - Business Wire

Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of 8.00% and 11.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Xencor: Q3 Earnings Insights

Xencor (NASDAQ:XNCR) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement.

6 months ago - Benzinga

Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 S...

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...

6 months ago - Business Wire

Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematol...

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoi...

6 months ago - Business Wire

Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS' Multidisciplina...

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...

6 months ago - Business Wire

Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoi...

6 months ago - Business Wire

Earnings Preview: Xencor (XNCR) Q3 Earnings Expected to Decline

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research